GTx shares dive as clot threat brings FDA clinical hold for prostate cancer product
This article was originally published in Scrip
Executive Summary
Shares of GTx sank after US regulators placed a clinical hold on Phase II studies of Capesaris (GTx-758), its investigational, nonsteroidal selective estrogen receptor alpha agonist, due to reports of an increased risk of blood clots in patients on the drug. GTx shares were down $2.11, or 36.3%, to $3.69 on 21 February.